Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx Withdrawal Has Not Affected Merck's Belief In DTC Advertising

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will continue to support its products with direct-to-consumer advertising campaigns despite the withdrawal of Vioxx, CEO Ray Gilmartin said Jan. 11 at the J.P. Morgan health care conference in San Francisco

You may also be interested in...



Vioxx DTC Ads Do Not Undercut “Learned Intermediary” Defense, Merck Says

“We think our DTC ads are wholly consistent with the philosophy underlying the learned intermediary rule,” General Counsel Frazier says. Merck expects the first Vioxx personal injury trial will commence in the first half of 2005 in either Texas or Alabama.

Merck/Schering Unbranded Ad Spotlights “Two Sources” Of High Cholesterol

The TV commercial launched three days after FDA approved the joint venture’s Zocor/Zetia combination Vytorin. The ad contains no suggestion of a branded product but highlights the hereditary and dietary causes of high cholesterol.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

Topics

UsernamePublicRestriction

Register

LL1130421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel